AYTU BioPharma, Inc. Common Stock
$2.00
$0.03 (+1.52%)
$1.97Day Range$2.15
Key Statistics
Market Cap
$21.14M
Shares Outstanding
10.7M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Feb 15, 2008
Round Lot
100
Locale
US
Trading Data
Day Open
$2.15
Day High
$2.15
Day Low
$1.97
Volume
7.1K
VWAP
$2.02
Prev Close
$1.97
Transactions
--
Acc. Volume
--
About AYTU BioPharma, Inc. Common Stock
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
PHARMACEUTICAL PREPARATIONSSIC 283483 employees7900 E. UNION AVENUE, DENVER, CO, 80237(720) 437-6580IPO Feb 15, 2008US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001385818
- Composite FIGI
- BBG000VC2PT9
- Share Class FIGI
- BBG001T21Q11
- Ticker Root
- AYTU
- SIC Code
- 2834
About AYTU BioPharma, Inc. Common Stock (AYTU) Stock
AYTU BioPharma, Inc. Common Stock (AYTU) closed the 2026-09-17 session at $2.00, up 1.52% versus the previous close (+0.03). The stock opened at $2.15 and traded between $1.97 and $2.15 during that session. Session trading volume was 7K shares. The volume-weighted average price (VWAP) is $2.02.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
AYTU BioPharma, Inc. Common Stock has a market capitalization of $21.1 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. AYTU is listed on the XNAS exchange. The company employs approximately 83 people. AYTU BioPharma, Inc. Common Stock is headquartered in DENVER, CO. The recorded listing date is 2008-02-15.
On this page you can find market AYTU stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.